Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04028063 · ClinicalTrials.gov registry record · Phase 2
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
A Phase 2 study of Metastatic Soft Tissue Sarcoma and Advanced Soft Tissue Sarcoma, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT04028063 is a Phase 2 study of Metastatic Soft Tissue Sarcoma and Advanced Soft Tissue Sarcoma that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 65 participants, below the 135-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04028063, a Phase 2 study of Metastatic Soft Tissue Sarcoma and Advanced Soft Tissue Sarcoma, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, non-randomized, single-institution, single arm Phase II study conducted using a Simon two-stage design with an additional safety lead-in. The overall objective is to determine the efficacy of combination doxorubicin with dual checkpoint blockade with anti-CTLA-4 antibody AGEN1884 and anti-PD-1 antibody AGEN2034. The investigators will estimate the progression-free survival rate at 6 months (PFS6mo) of doxorubicin plus AGEN1884/AGEN2034 in comparison to historical PFS6mo with doxorubicin monotherapy, calculated as the mean from two large randomized Phase 3 clinical trials.
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Balstilimab
- DRUG Zalifrelimab
- DRUG Botensilimab
Study Locations (1)
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2020-01-28 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04028063
The ClinicalTrials.gov registry entry for NCT04028063 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (52% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Soft Tissue Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which Doxorubicin is the first listed.
NCT04028063 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT04028063 about?
NCT04028063 is a clinical study titled "Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas". This is an open-label, non-randomized, single-institution, single arm Phase II study conducted using a Simon two-stage design with an additional safety lead-in. The overall objective is to determine the efficacy of combination doxorubicin with dual checkpoint blockade with anti-CTLA-4 antibody AGEN1...
What is the current status of trial NCT04028063?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2020-01-28. Estimated completion is 2027-12-31.
What conditions does trial NCT04028063 study?
This clinical trial studies the following conditions: Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma.
What interventions are being tested in trial NCT04028063?
The interventions under investigation include: Doxorubicin (DRUG), Balstilimab (DRUG), Zalifrelimab (DRUG), Botensilimab (DRUG).
Who is sponsoring clinical trial NCT04028063?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04028063 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
COMPLETED · Phase 2
-
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.